Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $501.39, for a total transaction of $4,763,205.00. Following the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $162,672,475.77. The trade was a 2.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

United Therapeutics Trading Down 0.1%

Shares of NASDAQ:UTHR traded down $0.63 during midday trading on Thursday, hitting $497.85. The company had a trading volume of 1,184,836 shares, compared to its average volume of 502,589. United Therapeutics Corporation has a 12 month low of $402.50 and a 12 month high of $609.35. The stock has a market cap of $21.35 billion, a price-to-earnings ratio of 17.81, a PEG ratio of 2.51 and a beta of 0.56. The firm has a fifty day simple moving average of $517.63 and a 200 day simple moving average of $540.68.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same period in the previous year, the firm earned $6.41 earnings per share. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. Equities analysts forecast that United Therapeutics Corporation will post 26.21 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on UTHR shares. Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. JPMorgan Chase & Co. raised their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Morgan Stanley set a $515.00 target price on United Therapeutics in a report on Thursday, August 6th. Finally, Royal Bank Of Canada decreased their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

Institutional Investors Weigh In On United Therapeutics

Several large investors have recently made changes to their positions in UTHR. Talon Private Wealth LLC boosted its stake in United Therapeutics by 31.8% in the 2nd quarter. Talon Private Wealth LLC now owns 6,753 shares of the biotechnology company’s stock worth $3,659,000 after purchasing an additional 1,630 shares during the period. Sequoia Financial Advisors LLC raised its stake in shares of United Therapeutics by 4.4% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 2,530 shares of the biotechnology company’s stock valued at $1,371,000 after purchasing an additional 106 shares during the period. Tidal Investments LLC raised its stake in shares of United Therapeutics by 1.6% in the 2nd quarter. Tidal Investments LLC now owns 34,012 shares of the biotechnology company’s stock valued at $18,429,000 after purchasing an additional 547 shares during the period. Archford Capital Strategies LLC bought a new stake in shares of United Therapeutics in the second quarter valued at about $552,000. Finally, Engineers Gate Manager LP bought a new stake in shares of United Therapeutics in the second quarter valued at about $2,524,000. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.